Fenfluramine for the Treatment of Dravet Syndrome and Lennox Gastaut Syndrome: A Review-Reference-Cited by-同舟云学术

Fenfluramine for the Treatment of Dravet Syndrome and Lennox Gastaut Syndrome: A Review

Published:2022-09-24 Issue:12 Volume:24 Page:631-640
ISSN:1092-8480
Container-title:Current Treatment Options in Neurology
language:en
Short-container-title:Curr Treat Options Neurol

Author:

Nordli Douglas R.^ORCID,Galan Fernando N.

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical)

Link

https://link.springer.com/content/pdf/10.1007/s11940-022-00741-4.pdf

Reference22 articles.

1. Sultana B, et al. Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis. Neurology. 2021;96(17):805–17.

2. Cross JH, et al. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure. 2021;93:154–9.

3. Administration, F. D. (1973). FINTEPLA® (fenfluramine) oral solution, CIV. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212102s000lbl.pdf.

4. Fuller RW, Snoddy HD, Robertson DW. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol Biochem Behav. 1988;30(3):715–21.

5. Zhang Y, et al. Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine. PLoS ONE. 2015;10(5):e0125898.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome;Expert Opinion on Pharmacotherapy;2023-06-05